Sentinus LLC’s Novartis NVS Stock Holding History

Sentinus LLC’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$221K	Buy	+1,412	New	+$212K	0.02%	578
2024 Q4	–	Sell	-1,894	Closed	-$218K	–	191
2024 Q3	$218K	Buy	+1,894	New	+$215K	0.07%	172

Other funds holding NVS

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Sentinus LLC's NVS Position: Q2 2026 in Review

Sentinus LLC opened a new position in Novartis (NVS) in Q2 2026: 1,412 shares worth $221K. The stake represents 0.02% of the portfolio and ranks #578 among its holdings. This is a return to the name: Sentinus LLC previously reported a position in NVS as recently as Q3 2024.

Sentinus LLC first reported a position in NVS in Q3 2024 and has held it in 2 quarters since. 1,621 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

Sentinus LLC held 1,412 shares of Novartis worth $221K as of Q2 2026.
Novartis was a new Sentinus LLC position in Q2 2026.
Novartis made up 0.02% of Sentinus LLC's portfolio in Q2 2026, its #578 holding.
Sentinus LLC first reported a position in Novartis in Q3 2024 and has held it in 2 quarters since.
1,621 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Sentinus LLC's 13F filing for Q2 2026, filed 11 Aug 2026.